Wakefield Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-21,567
Closed -$1.79M 212
2022
Q4
$1.79M Buy
21,567
+411
+2% +$33.3K 0.76% 49
2022
Q3
$1.68M Buy
+21,156
New +$1.78M 0.77% 49
2022
Q2
Sell
-11,924
Closed -$1.07M 212
2022
Q1
$1.07M Buy
+11,924
New +$1.1M 0.38% 76

Other funds holding XBI

Wakefield Asset Management's XBI Position: Q1 2023 in Review

Wakefield Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2023, closing a stake of 21,567 shares — an estimated $1.79M sold.

Wakefield Asset Management first reported a position in XBI in Q1 2022 and held it in 3 quarters. The position peaked at $1.79M in Q4 2022. 712 funds tracked by Wall St. Rank hold XBI as of Q1 2023.

  • Wakefield Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2023 after selling out during the quarter.
  • Wakefield Asset Management sold 21,567 State Street SPDR S&P Biotech ETF shares in Q1 2023, an estimated $1.79M.
  • Wakefield Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and held it in 3 quarters.
  • Wakefield Asset Management's State Street SPDR S&P Biotech ETF position peaked at $1.79M in Q4 2022.
  • 712 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2023.

Based on Wakefield Asset Management's 13F filing for Q1 2023, filed 2 May 2023.